In a previous study, Solit et al. (2005) performed a similar study of wild-type EGFR breast cancer cells-generated nude mouse xenografts [32] and showed that compared to a 5-day continuous administration of paclitaxel, gefitinib treatment at a dose of 65 mg/kg for 2 days before paclitaxel had obvious antitumor activity and that a 150 mg/kg gefitinib had the best tumor inhibition, suggesting the higher dose of EGFR-TKI pretreatment resulted in a better antitumor activity [32], while our current study showed the similar data and therefore confirmed their data. The gene discussed is EGFR; the disease is neoplasm.